Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Prospective Evaluation of the Optimal SCS Trial Length

5 de octubre de 2026 actualizado por: Ohio State University

This study aims to determine the ideal length of a spinal cord stimulation (SCS) trial period by analyzing daily pain scores, patient satisfaction, and when patients decide whether to proceed with permanent implantation. The primary goal is to identify the shortest trial duration that can reliably predict SCS success. A secondary goal is to compare SCS trial outcomes with patient-reported health measures (PROMIS domains) and recommendations from the SCS E-Health Tool to evaluate how well these tools predict treatment candidacy and outcomes.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

Spinal cord stimulation (SCS) is an established treatment for chronic pain and is typically preceded by a temporary trial period to evaluate treatment effectiveness before permanent implantation. Standard SCS trial durations generally range from 3 to 7 days, although some trials may be extended up to 15 days. These timeframes are largely intended to minimize the risk of epidural infection associated with prolonged epidural lead placement. However, there is limited evidence defining the optimal duration of an SCS trial, raising the possibility that many trials may be longer than clinically necessary (1).

Reducing the duration of SCS trials could provide several clinical benefits. Shorter trials may decrease the risk of infection, reduce the need for prophylactic antibiotic exposure, and minimize the length of time patients must interrupt antiplatelet or anticoagulant therapy when applicable. Determining the shortest trial duration that reliably predicts treatment success could improve patient safety while streamlining clinical care.

This study aims to identify the optimal duration of the SCS trial by evaluating daily pain scores, patient satisfaction, and the timing of patients' decisions to proceed with permanent SCS implantation. The primary objective is to determine the minimum number of trial days required to accurately predict SCS trial success. The secondary objective is to evaluate the association between SCS trial outcomes and patient-reported outcome measures, including PROMIS domain scores and candidacy recommendations generated by the SCS E-Health Tool, to assess their ability to predict SCS candidacy and treatment outcomes.

Tipo de estudio

De observación

Inscripción (Estimado)

42

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • The Ohio State University
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Certain populations will be excluded to minimize factors that may influence pain reporting, treatment response, and SCS trial outcomes. Exclusions include pregnant individuals, those involved in active worker's compensation claims, patients with prior failed SCS trials, and individuals using chronic opioids exceeding 50 MME/day. These criteria help ensure participant safety, reduce potential confounding variables, and improve the accuracy and validity of the study findings.

Descripción

Inclusion Criteria:

  1. Adults aged 18 years or older who are able to provide informed consent.
  2. Individuals with a clinical diagnosis of a chronic pain condition deemed appropriate for spinal cord stimulation (SCS) therapy by the treating physician.
  3. Individuals with a documented duration of chronic pain greater than 12 weeks.
  4. Individuals scheduled to undergo a spinal cord stimulation trial as part of routine clinical care at a participating site.

Exclusion Criteria:

  1. Pregnant individuals.
  2. Individuals currently receiving or involved in a worker's compensation claim related to their pain condition.
  3. Individuals with a history of a previously failed spinal cord stimulation (SCS) trial.
  4. Individuals with chronic opioid use exceeding 50 morphine milligram equivalents (MME) per day.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
SCS Trial Participants

Participants undergoing a standard spinal cord stimulation (SCS) trial as part of routine clinical care will be observed. Daily pain scores, patient satisfaction, and decision-making regarding permanent SCS implantation will be collected during the trial period. No study-specific intervention will be administered; the study evaluates outcomes associated with the existing SCS trial process.

This observational study will enroll approximately 42 subjects at The Ohio State University who are undergoing a spinal cord stimulation (SCS) trial as part of standard clinical care. No study-specific intervention will be assigned. Participants will be monitored to evaluate SCS trial outcomes, including pain scores, patient satisfaction, and decisions regarding permanent implantation. The sample size was selected to provide sufficient evaluable data while accounting for potential attrition and supporting descriptive and exploratory analyses.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Determination of the Minimum SCS Trial Duration Predictive of Clinical Outcomes
Periodo de tiempo: 15 days

Determining the minimum number of days required to accurately predict SCS trial outcomes.

15 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Correlation Between Baseline PROMIS Domain T-Scores and Final SCS Trial Outcome
Periodo de tiempo: 15 days

Assessment of the correlation between baseline Patient-Reported Outcomes Measurement Information System (PROMIS) domain T-scores (Pain Interference, Physical Function, Depression, Anxiety, and Sleep Disturbance) and the final spinal cord stimulation (SCS) trial outcome (successful vs. unsuccessful trial).

15 days
Correlation Between Baseline SCS E-Health Tool Candidacy Recommendation and Final SCS Trial Outcome
Periodo de tiempo: 15 days

Assessment of the correlation between the baseline SCS E-Health Tool candidacy recommendation and the final spinal cord stimulation (SCS) trial outcome (successful vs. unsuccessful trial).

15 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

28 de octubre de 2026

Finalización primaria (Estimado)

31 de agosto de 2029

Finalización del estudio (Estimado)

31 de agosto de 2029

Fechas de registro del estudio

Enviado por primera vez

7 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

13 de julio de 2026

Publicado por primera vez (Actual)

16 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de octubre de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

The current study plan does not indicate an intention to make individual participant data (IPD) available to other researchers. Study findings will be analyzed and reported in aggregate form, and no external sharing of participant-level data is planned.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir